Cell-free circulating RAS mutation concentrations significantly impact the survival of metastatic colorectal cancer patients.
Axel MuendleinKathrin GeigerChristine HeinzleStella GaengerThomas WinderLuciano SevergniniPatrick ReimannEva Maria BrandtnerAndreas LeihererHeinz DrexelThomas DeckerChristoph NonnenbroichTobias DechowPublished in: Journal of cancer research and clinical oncology (2023)
Our results emphasize the clinical value of circulating RAS mutations in managing mCRC.